The effects of Egr-1 overexpression on these outcomes were elucidated using a C6 glioma cell model with decreased histone acetylation in GDNF promoter II following treatment with the histone acetyltransferase (HAT) inhibitor curcumin [22–24]. This evidence concerns the gene GDNF and glioma.